IL97709A - Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis - Google Patents
Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosisInfo
- Publication number
- IL97709A IL97709A IL9770991A IL9770991A IL97709A IL 97709 A IL97709 A IL 97709A IL 9770991 A IL9770991 A IL 9770991A IL 9770991 A IL9770991 A IL 9770991A IL 97709 A IL97709 A IL 97709A
- Authority
- IL
- Israel
- Prior art keywords
- multiple sclerosis
- directed
- medicament
- preparation
- treatment
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 1
- 102000047918 Myelin Basic Human genes 0.000 abstract 1
- 101710107068 Myelin basic protein Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 102000054064 human MBP Human genes 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- -1 vaccines Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Pathology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50255990A | 1990-03-30 | 1990-03-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL97709A0 IL97709A0 (en) | 1992-06-21 |
| IL97709A true IL97709A (en) | 2005-05-17 |
Family
ID=23998362
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165071A IL165071A (en) | 1990-03-30 | 1991-03-28 | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
| IL9770991A IL97709A (en) | 1990-03-30 | 1991-03-28 | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
| IL16507104A IL165071A0 (en) | 1990-03-30 | 2004-11-07 | The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165071A IL165071A (en) | 1990-03-30 | 1991-03-28 | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16507104A IL165071A0 (en) | 1990-03-30 | 2004-11-07 | The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0522091B9 (de) |
| JP (1) | JPH05507911A (de) |
| AT (1) | ATE210721T1 (de) |
| AU (1) | AU651350B2 (de) |
| BR (1) | BR9106303A (de) |
| CA (1) | CA2078549C (de) |
| DE (1) | DE69132863T2 (de) |
| DK (1) | DK0522091T5 (de) |
| ES (1) | ES2169021T3 (de) |
| HU (1) | HU217847B (de) |
| IL (3) | IL165071A (de) |
| NO (1) | NO308611B1 (de) |
| WO (1) | WO1991015225A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207645B1 (en) * | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| CA2081672A1 (en) * | 1990-05-01 | 1991-11-02 | Lawrence Steinman | T-cell receptor variable transcripts as disease related markers |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| EP0722738A3 (de) * | 1991-01-22 | 1996-10-23 | Immune Response Corp Inc | Impfung und Verfahren gegen Krankheiten, die von pathologischen Reaktionen durch spezifischen T-Zellpopulation abstammen |
| US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| AU3418893A (en) * | 1991-12-24 | 1993-07-28 | Immune Response Corporation, The | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| US5891435A (en) * | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
| AU2950195A (en) * | 1994-07-01 | 1996-01-25 | Connective Therapeutics Inc. | Methods for diagnosing an immune-related disease and choosing an immune-related therapy |
| SI9520118A (sl) * | 1994-10-25 | 1998-08-31 | Immulogic Pharmaceutical Corporation | Sestavki in zdravljenje multiple skleroze |
| US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
| IL114458A0 (en) * | 1995-07-05 | 1995-11-27 | Yeda Res & Dev | Therapeutic preparations for treatment of T cell mediated diseases |
| US20020009448A1 (en) * | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
| JP4986361B2 (ja) | 2000-05-24 | 2012-07-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｅ−セレクチンに対する寛容誘導による脳卒中防止法 |
| BRPI0113400B1 (pt) * | 2000-08-21 | 2018-05-15 | Apitope Technology Bristol | Método para seleção de peptídeo |
| US7658926B2 (en) | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| JP2005528910A (ja) * | 2002-06-05 | 2005-09-29 | ベイラー カレッジ オブ メディシン | Ｔ細胞レセプターｃｄｒ３配列および検出のための方法 |
| US7744893B2 (en) | 2002-06-05 | 2010-06-29 | Baylor College Of Medicine | T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same |
| CN100567987C (zh) | 2002-08-08 | 2009-12-09 | 贝勒医学院 | T细胞疫苗及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2072356A1 (en) * | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
-
1991
- 1991-03-28 IL IL165071A patent/IL165071A/en not_active IP Right Cessation
- 1991-03-28 IL IL9770991A patent/IL97709A/xx not_active IP Right Cessation
- 1991-03-29 AT AT91910085T patent/ATE210721T1/de not_active IP Right Cessation
- 1991-03-29 BR BR919106303A patent/BR9106303A/pt not_active Application Discontinuation
- 1991-03-29 DK DK91910085T patent/DK0522091T5/da active
- 1991-03-29 HU HU9203100A patent/HU217847B/hu unknown
- 1991-03-29 CA CA002078549A patent/CA2078549C/en not_active Expired - Lifetime
- 1991-03-29 DE DE69132863T patent/DE69132863T2/de not_active Expired - Lifetime
- 1991-03-29 EP EP91910085A patent/EP0522091B9/de not_active Expired - Lifetime
- 1991-03-29 AU AU78989/91A patent/AU651350B2/en not_active Expired
- 1991-03-29 ES ES91910085T patent/ES2169021T3/es not_active Expired - Lifetime
- 1991-03-29 WO PCT/US1991/002218 patent/WO1991015225A1/en not_active Ceased
- 1991-03-29 JP JP91509347A patent/JPH05507911A/ja active Pending
-
1992
- 1992-09-29 NO NO923778A patent/NO308611B1/no not_active IP Right Cessation
-
2004
- 2004-11-07 IL IL16507104A patent/IL165071A0/xx active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP0522091B1 (de) | 2001-12-12 |
| AU7898991A (en) | 1991-10-30 |
| HUT63334A (en) | 1993-08-30 |
| IL165071A0 (en) | 2005-12-18 |
| ATE210721T1 (de) | 2001-12-15 |
| HU9203100D0 (en) | 1992-12-28 |
| HU217847B (hu) | 2000-04-28 |
| IL165071A (en) | 2008-06-05 |
| WO1991015225A1 (en) | 1991-10-17 |
| DE69132863D1 (de) | 2002-01-24 |
| BR9106303A (pt) | 1993-04-13 |
| AU651350B2 (en) | 1994-07-21 |
| EP0522091A1 (de) | 1993-01-13 |
| DK0522091T3 (da) | 2002-04-08 |
| CA2078549A1 (en) | 1991-10-01 |
| ES2169021T3 (es) | 2002-07-01 |
| EP0522091B9 (de) | 2007-11-21 |
| NO923778L (no) | 1992-11-16 |
| DK0522091T5 (da) | 2008-06-23 |
| NO308611B1 (no) | 2000-10-02 |
| IL97709A0 (en) | 1992-06-21 |
| DE69132863T2 (de) | 2002-06-20 |
| NO923778D0 (no) | 1992-09-29 |
| EP0522091A4 (en) | 1993-05-26 |
| JPH05507911A (ja) | 1993-11-11 |
| CA2078549C (en) | 2006-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL97709A (en) | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis | |
| GB2255093A (en) | Hiv-1 core protein fragments | |
| GR990300020T1 (en) | Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg | |
| ES2181676T3 (es) | Diagnosis y tratamiento de enfermedades autoinmunitarias. | |
| IL99401A (en) | Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations | |
| PL311660A1 (en) | Viral vectors and their application in genic therapy | |
| EP0458079A3 (en) | Ultrasonic contrast agent, its preparation and application as diagnostic or therapeutic | |
| NL300156I1 (nl) | Therapeutische toepassing van chimere en radioactief gemerkte antilichamen tegen humane B-Lymfocyt beperkt differentiatie antigeen voor de behandelingvan B-Cel lymfoom. | |
| GR3035440T3 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
| GB2213823B (en) | Synthetic peptides for use in the diagnosis and prevention of influenza virus infection | |
| DE69628844D1 (de) | Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose | |
| GR3022092T3 (en) | Therapeutic method for iddm. | |
| GR3035152T3 (en) | Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens | |
| EP0222310A3 (de) | Verfahren zur Diagnose von Multiple-Sklerose | |
| HK141494A (en) | Peptide fragments of HIV | |
| ES2012997A6 (es) | Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal. | |
| NZ515332A (en) | Lawsonia derived gene and related SodC polypeptides, peptides and proteins and their uses | |
| EP0601108A4 (en) | Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects. | |
| NZ224251A (en) | Synthetic rhinovirus (hrv) peptides and vaccines | |
| DE68918127D1 (de) | Peptidbehandlung von hartnäckigen Infektionskrankheiten. | |
| AU2065488A (en) | The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent | |
| 杨春普 | ACUPUNCTURE OF GUANYUAN (REN 4) AND BAIHUI (DU 20) IN THE TREATMENT OF 500 CASES OF ENURESIS | |
| SE9704451D0 (sv) | New method and compositions for the treatment of autoimmune diseases | |
| HU9200147D0 (en) | Medical preparations with human interleukin-2 content | |
| GB9618119D0 (en) | Adjuvants for use in vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |